Merck & Co., Inc. (MRK)
Merck to buy EyeBio in a deal that could valued at up to $3 billion
Merck & Co. Inc. MRK, -2.63% announced Wednesday an agreement to buy privately held Eyebiotech Ltd., an ophthalmology-focused biotechnology company, in a deal that could be valued at up to $3 billion.
Merck nears $1.3 bln cash deal for eye-drug company EyeBio, WSJ reports
Merck & Co is nearing a $1.3 billion cash deal to buy ophthalmology biotechnology company Eyebiotech in an agreement that could see an additional $1.7 billion in milestone payments, the Wall Street Journal reported on Tuesday.
Sell Alert: 2 Dividend Stocks To Sell In May And Go Away
The "Sell in May and go away" adage suggests selling stocks in May and returning in November, but historical data shows that June and July have been strong months. September is consistently the worst month for the stock market, with unpredictable returns, while November has historically been the best month. Selling stocks should be based on valuation rather than following a seasonal strategy, focusing on rotating out of overvalued stocks and into undervalued ones.
HPV vaccine provides real benefits for men, analysis shows
Vaccination of boys and men against the human papillomavirus (HPV) reduces their risk of head and neck cancers and other malignancies, a new analysis shows, adding to the vaccine's proven benefit in protecting women from cervical cancer.
HPV vaccine can have big benefits for men, research shows
A vaccine that's widely known to help protect women from cervical cancer can also offer big health benefits for men, new research shows.
Why Merck (MRK) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Merck (MRK) Crossed Above the 20-Day Moving Average: What That Means for Investors
Merck (MRK) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MRK broke through the 20-day moving average, which suggests a short-term bullish trend.
